Journal Information
Vol. 14. Issue 5.
Pages 536-539 (September - October 2010)
Share
Share
Download PDF
More article options
Vol. 14. Issue 5.
Pages 536-539 (September - October 2010)
Case report
Open Access
Fatal Strongyloides stercoralis hyper-infection in a patient with multiple myeloma
Visits
2358
Mohamed A. Yassin
Corresponding author
yassin160@yahoo.co.uk

Correspondence to: Al-Amal Hospital P.O.BOX 3050 Doha QATAR Tel.: +974 4397807 /+974 4397895 Fax: +974 4397857.
, Halima El Omri, Ibrahim Al-Hijji, Ruba Taha, Reham Hassan, Kamal Al Aboudi, Hanadi El-Ayoubi
Hematology Department, Al Amal Hospital
This item has received

Under a Creative Commons license
Article information
Abstract

Strongyloides stercoralis (S.S.) is a human intestinal parasite, which may lead to complicated strongyloidiasis. We report a case of disseminated strongyloidiasis following the treatment of myeloma. The patient developed skin lesions, respiratory distress, aseptic meningitis and bacterial and fungal sepsis. The diagnosis of strongyloidiasis was established through endotracheal tube secretions. Despite the treatment with Ivermectin and Albendazole, the outcome was fatal. The value of screening for strongyloidiasis is unclear but may be of benefit in patients with hematological malignancies from high endemic areas.

Keywords:
acute respiratory failure
disseminated strongyloidiasis
myeloma
steroids
Full text is only aviable in PDF
References
[1.]
A.A. Siddiqui, S.L. Berk.
Diagnosis of Strongioloides stercoralis Infection.
Clin Infect Dis, 33 (2001), pp. 1040-1047
[2.]
R.M. Genta.
Global prevalence of strongyloidiasis: Critical review with epidemiologic insights into the prevention disseminated disease.
Rev Infect Dis, 11 (1989), pp. 755-767
[3.]
P.B. Keiser, T.B. Nutman.
Strongyloides stercoralis in the immunocompromised population.
Clin Microbiol Rev, 17 (2004), pp. 208-217
[4.]
C.J. Hunter, M. Petrosyan, M. Asch.
Dissemination of Strongyloides stercoralis in a patient with systemic lupus erythematous after initiation of Albendazole: A case report.
J Med Case Report, 2 (2008), pp. 156-164
[5.]
S. Namisato, K. Motomura, S. Haranaga, et al.
Pulmonary strongyloidiasis in a patient receiving prednisolone therapy.
Inter Med, 43 (2004), pp. 731-735
[6.]
M.S. Newnham.
Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection.
Ann Pharmacother, 41 (2007), pp. 1992-2001
[7.]
H. Orlent, C. Crawley, K. Cwynarski, R. Dina, J. Apperly.
Strongyloidiasis pre and post Autologous peripheral blood stem cell transplantation.
Bone Marrow Transplant, 32 (2003), pp. 115-117
[8.]
E.M. Carvalho, Dafonseca, A. Porto.
Epidemiological and clinical interaction Between HTLV-1 and Strongyloides stercoralis.
Parasites Immunol, 26 (2004), pp. 487-497
[9.]
H.L. Rotman, W. Yutanawiboonchai, R.A. Brigande, et al.
Strongyloidess stercoralis: Eosinophil-dependant immune-mediated killing of third stage larvae in BALB/cByJ mice.
Exp Parasitol, 82 (1996), pp. 267-278
[10.]
R. Concha, W. Harrington, A.I. Rogers.
Intestinal strongyloidiasis recognition management, and determinant of outcomes.
J Clin Gastrointerol, 39 (2005), pp. 203-211
[11.]
A.M. Newberry, D.N. Williams, W.M. Stauffer, et al.
Strongyloides hyperinfection presenting as acute respiratory failure and gramnegative sepsis.
Chest, 128 (2005), pp. 3681-3684
[12.]
S. Lim, K. Katz, S. Kratjden, et al.
Complicated and fatal strongyloides infection in Canadian: risk factors, diagnosis and management.
CMAJ, 171 (2004), pp. 479-484
[13.]
R. Igual-Adell, C. Oltra-Alcaraz, E. Soler-Company, et al.
Efficacy and safety of Ivermectin and Thiabendazole in the treatment of strongyloidiasis.
Expert Opinion Pharmacother, 5 (2004), pp. 2615-2619
[14.]
P. Muennig, D. Pallin, C. Challah, et al.
The cost effectiness of Ivermectin vs. Albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States.
Epidemiol Infect, 132 (2004), pp. 1055-1063
Copyright © 2010. Elsevier Editora Ltda.. All rights reserved
The Brazilian Journal of Infectious Diseases
Article options
Tools